Mechanisms of Pyrazinamide Action and Resistance.
Ying Zhang, Wanliang Shi, Wenhong Zhang...
https://pubmed.ncbi.nlm.nih.gov/26104205/Actively Recruiting
Led by Shenzhen Third People's Hospital · Updated on 2025-12-01
610
Participants Needed
3
Research Sites
47 weeks
Total Duration
Pulmonary tuberculosis TB remains a major global health challenge, especially in China, which has a high burden of both drug-susceptible and drug-resistant TB cases. Researchers are evaluating a new ultra-short-course treatment regimen called PAN-TB that aims to be effective for all active TB types. This regimen seeks to simplify treatment, reduce costs, shorten treatment duration to 2-3 months, and improve safety and success rates compared to standard care. The study compares multiple treatment regimens including a 2-month bedaquiline, linezolid, sitafloxacin, and pyrazinamide BLSZ regimen with possible extensions up to 13 weeks, a standard 6-month regimen using isoniazid, rifampicin, pyrazinamide, and ethambutol, and a 6-month bedaquiline, pretomanid, linezolid, and moxifloxacin BPaLM regimen with potential extension to 9 months if needed. Each treatment arm is tailored for either drug-susceptible or drug-resistant TB, and adjustments are made based on sputum smear or culture results and clinical symptoms. Participants will undergo regular follow-up visits for up to 18 months to monitor treatment outcomes and safety. Assessments include sputum culture conversion, clinical symptom evaluation, chest imaging, laboratory tests, and adverse event monitoring. The primary outcomes focus on unfavorable outcomes at 12 months and safety at 2 months, with additional secondary outcomes tracking longer-term treatment success and side effects. The study also aims to identify new biomarkers linked to treatment responses throughout the therapy.
CONDITIONS
A PAN-USR TB Multi-Center Trial
P
Professor Lu
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shenzhen Third People's Hospital
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 9 to 26 weeks depending on regimen and response, with possible extensions up to 13 or 39 weeks
Participants receive drug regimens specific to their tuberculosis type. Drug-susceptible TB participants receive either a 9-week regimen of bedaquiline, linezolid, sitafloxacin, and pyrazinamide (extendable to 13 weeks if needed) or a 26-week regimen starting with isoniazid, rifampicin, pyrazinamide, and ethambutol followed by isoniazid and rifampicin. Drug-resistant TB participants receive either the same 9 to 13-week bedaquiline-based regimen or a 6-month regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin, extendable to 9 months if conditions do not improve.
Weekly or periodic visits during treatment depending on regimen and clinical status
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Ying Zhang, Wanliang Shi, Wenhong Zhang...
https://pubmed.ncbi.nlm.nih.gov/26104205/Bern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis...
https://pubmed.ncbi.nlm.nih.gov/36546625/Bern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis...
https://pubmed.ncbi.nlm.nih.gov/37980911/Ying Zhang, Kwok Chiu Chang, Chi-Chiu Leung...
https://pubmed.ncbi.nlm.nih.gov/26038418/Francesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov...
https://pubmed.ncbi.nlm.nih.gov/36053506/Liang Fu, Xilin Zhang, Juan Xiong...
https://pubmed.ncbi.nlm.nih.gov/37567554/Nicholas I Paton, Christopher Cousins, Celina Suresh...
https://pubmed.ncbi.nlm.nih.gov/36808186/Shenzhen Third People's Hospital
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Collaborating Sponsor